- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02545140
Prevention Strategies for Adolescents at Risk of Diabetes (PRE-STARt)
Prevention Strategies for Adolescents at Risk of Diabetes - Validation of a Risk Tool for Young People Aged 12 - 14 Years
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Data will be collected in 5 European Commission countries (500 adolescents in total). A range of biological and lifestyle measures will be collected in order to investigate the adolescent's lifestyle and will include body weight and other anthropometric measurements, blood pressure, blood capillary sample, self-reported physical activity, sedentary behaviour and dietary habits. Their parent/guardian will complete a number of questions to gather information about variables that have been associated with chronic disease (including type 2 diabetes) and include peri-natal history (birth weight, gestational diabetes), socioeconomic status, family health and medical history.
A draft risk tool to identify those children with a 'higher risk' of developing type 2 diabetes in the future has been developed systematic review results and a Delphi procedure. This draft tool will be evaluated and refined. This draft risk tool will be evaluated by independent clinical reviewers against the data collected from the 500 adolescent data sets. The results for each adolescent will be independently reviewed by clinicians who will assign either a "lower" or "higher" risk to each case. The results will be compared to the results from the draft 'PRE-START tool', used to further refine this identification tool using appropriate statistical methods.
The outputs of this study will be a fit for purpose 'PRE-STARt tool' that can be used for recruitment to interventional studies whose primary objective is to reduce the risk of developing chronic disease (including type 2 diabetes) in the future.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Leicester, Royaume-Uni, LE4 5pW
- University Hospitals of Leicester
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Young people aged between 12-14 years of age
- be willing and able to give assent
- have obtained written parent/guardian consent.
Exclusion Criteria:
- are outside the age range of interest (i.e. aged less than 12 years or greater than 14 years of age)
- do not have parental consent or do not give assent
- have an existing diagnosis of type 1 or type 2 diabetes
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
UK (Lead Site)
Data will be collected from 100 adolescents from each participating site providing clinical data for 500 adolescents providing a cross-sectional cohort from each of the following countries: UK (Lead Site) Germany Portugal Greece Spain (Basque Country) |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Chronic disease risk factor - Body mass index (BMI)
Délai: 12 months
|
Height and weight will be measured to calculated BMI
|
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Chronic disease risk factor - waist circumference
Délai: 12 months
|
12 months
|
|
Chronic disease risk factor - blood pressure
Délai: 12 months
|
12 months
|
|
Chronic disease risk factor - glycated haemoglobin (HbA1c)
Délai: 12 months
|
12 months
|
|
Chronic disease risk factor - high density lipoprotein cholesterol
Délai: 12 months
|
12 months
|
|
Chronic disease risk factor - glucose
Délai: 12 months
|
Fasted and/or unfasted
|
12 months
|
Chronic disease risk factor - low density lipoprotein cholesterol
Délai: 12 months
|
Calculated
|
12 months
|
Chronic disease risk factor - triglycerides
Délai: 12 months
|
12 months
|
|
Chronic disease risk factor - total cholesterol
Délai: 12 months
|
12 months
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Risk tool refinement
Délai: 18 months
|
A draft risk tool to identify those children with a 'higher risk' of developing type 2 diabetes in the future that has been developed systematic review results and a Delphi procedure.
Each adolescent will complete a diet and lifestyle questionnaire about their physical activity, sedentary behaviour and dietary habits and the parent/guardian will complete a questionnaire about their family health history and about their child's early years (including gestational period, birth weight, whether they were breast or bottle fed).
This draft tool will be evaluated and refined using these data and the data from the assessments mentioned in 1-9.
The draft risk tool will then be refined based on data from the 500 adolescents using appropriate statistical methods resulting in an externally validated risk tool that can be used to screen young people aged between 12-14 years for being at risk of developing of type 2 diabetes in the future.
|
18 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Melanie J Davies, MD, University Hospitals, Leicester
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 173431
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète de type 2
-
Bnai Zion Medical CenterInconnue
-
Jiangsu HengRui Medicine Co., Ltd.Complété
-
Asahi Kasei Pharma CorporationRecrutement
-
University of MinnesotaActif, ne recrute pasHypoglycémie | Diabète sucré de type 2États-Unis
-
University of Campania "Luigi Vanvitelli"ComplétéDiabète sucré de type 2Italie
-
University of LiverpoolAstraZeneca; Clinical Practice Research DatalinkActif, ne recrute pas
-
Regor Pharmaceuticals Inc.RésiliéDiabète sucré de type 2États-Unis
-
Charles Drew University of Medicine and ScienceNational Center for Research Resources (NCRR)Résilié
-
Population Health Research InstituteNovo Nordisk A/SComplétéDiabète sucré de type 2Canada
-
Northwell HealthPatient-Centered Outcomes Research InstituteComplétéDiabète sucré de type 2 | Diabète de type 2États-Unis
Essais cliniques sur Aucune intervention
-
Otsuka Pharmaceutical Factory, Inc.CelerionComplété
-
University of MinnesotaComplété
-
Assistance Publique - Hôpitaux de ParisComplété
-
Milton S. Hershey Medical CenterPas encore de recrutementMaladies du foie | NASH - Stéatohépatite non alcoolique | NASH
-
University of CologneComplétéAccident vasculaire cérébral | ApraxieAllemagne
-
Northwestern UniversityComplétéLa dépression | AnxiétéÉtats-Unis
-
H2O Health and Agriculture LLCInconnuePneumonie | DiarrhéeGuatemala
-
Eunah Cho, MDComplétéRécupération postopératoireCorée, République de
-
University of California, Los AngelesInconnue
-
Johns Hopkins UniversityAstraZenecaInscription sur invitationCancer du poumon non à petites cellules (NSCLC)États-Unis